|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 9/20 | (2006.01) |
| A61K 31/4545 | (2006.01) | ||
| A61P 7/02 | (2006.01) |
| (11) | Number of the document | 3251660 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17175788.3 |
| Date of filing the European patent application | 2011-02-24 | |
| (97) | Date of publication of the European application | 2017-12-06 |
| (45) | Date of publication and mention of the grant of the patent | 2019-10-16 |
| (46) | Date of publication of the claims translation | 2019-12-10 |
| (30) | Number | Date | Country code |
| 308056 P | 2010-02-25 | US |
| (72) |
PATEL, Jatin, US
FROST, Charles, US
JIA, Jingpin, US
VEMA-VARAPU, Chandra, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
Bristol-Myers Squibb Holdings Ireland Unlimited Company, Hinterbergstrasse 16, 6312 Steinhausen, CH |
| (74) |
Otilija KLIMAITIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Apiksabano vaistinės formos |
| APIXABAN FORMULATIONS |
| Payment date | Validity (years) | Amount | |
| 2024-01-26 | 14 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2024-01-31 |